Genfit cans phase 3 NASH trial after failing interim analysis Roche drops hep B antiviral as late-stage pipeline tests 'largely on track' despite COVID-19 disruption Longwood banks $175M in its latest biotech fund Sponsored: Rise in Targeted Therapies Drives Need for Flexible Small-Volume Manufacturing Borisy's EQRx bags rights to EGFR inhibitor to drive discount me-too plan Olema Oncology grabs $54M for breast cancer program Preventing heart attacks by changing how platelets respond to blood flow stress Planning ahead: U.S., Canada order 177M more COVID-19 vaccine syringes from BD Featured Story | By Nick Paul Taylor Genfit is set to terminate its phase 3 nonalcoholic steatohepatitis (NASH) trial after concluding it is unlikely to generate data to support approval. The action eliminates a long-time front-runner in the now-stuttering race to bring a NASH treatment to market. read more |
| |
|---|
|
Top Stories By Ben Adams Roche has canned a phase 1 test of a potential hepatitis B antiviral as part of its third-quarter clean-up of unwanted pipeline drugs. read more By Amirah Al Idrus Longwood Fund is topping up its coffers with $175 million for its fifth biotech-building fund. Aptly dubbed Fund V, it is nearly double the VC shop’s first fund of $85 million, raised in 2010. The firm will continue to create new companies, as well as back early rounds for established companies. read more By Patheon, by Thermo Fisher Scientific Ensuring cohesion between drug substance chemists & drug product formulators is critical to manage risks & maximize rewards of transforming less soluble & bioavailable molecules into effective drugs. read more By Nick Paul Taylor Alexis Borisy’s EQRx has secured the ex-China rights to Hansoh Pharmaceutical’s almonertinib. The deal sets EQRx up to work the EGFR inhibitor into its plan to market me-too drugs at radical discounts to incumbent products. read more By Amirah Al Idrus Olema Oncology, a biotech focused on women’s cancers, raised $54 million to push its lead program into the clinic and boost its R&D efforts in other areas. The capital will bankroll a phase 1/2 study of the asset, OP-1250, as a single agent in patients with ER-positive, HER2-negative breast cancer. read more By Angus Liu Existing clot busters have one major drawback: They can block the proper functioning of platelets, thereby increasing the risk of uncontrolled bleeding. A research team led by Monash University has found a way to target platelet activation in a manner that appears to address the pathological clumping of blood. read more By Conor Hale Many countries are working to have the necessary medical infrastructure in place before a COVID-19 vaccine is proven effective. And now, as promising data begins to trickle in from a number of drugmakers, the U.S. is nearly quadrupling its orders for needles and syringes made by BD. read more | | Capture more value with your biotech equity Strategic planning for your early stage equity can result in a tax savings of up to $10 million as Qualified Small Business Stock. Harness works with serial scientific co-founders from top academic institutions and high growth company executives to find specialized financial advisors to help them capture more equity value. Learn more. |
Resources Sponsored by: Lonza Pharma & Biotech A novel spray-dried dispersion platform has been developed to faciliate high drug load applications Sponsored by: Florence Complimentary Download: How to connect to study sites remotely via the Electronic Investigator Site File (eISF) to streamline clinical operations. Insights from the largest eISF network in the world. Sponsored by: PRA Health Sciences Collaboration across the industry will be key to meeting the demands of the RACE Act and ensuring pediatric patients receive the care and treatments they need. With today’s rapidly evolving environment, we have created this five-part content series to highlight pressing issues and topics that are more pertinent today than ever before. Sponsored by: Cambrex The industry trend of outsourcing to CDMOs continues. With more services, capabilities, facilities, and employees than ever before, our experts have contributed more articles to our biggest eBook yet. Sponsored by: EVERSANA How predictive analytics and machine learning have the potential to transform healthcare by predicting “Patient Switching Behaviors.” Sponsored by: Recro Gainesville Wurster processing is a versatile technique for developing and manufacturing multiparticulates for modified release dosage forms. Read this whitepaper to determine whether Wurster processing is the right option for your project. Sponsored by: Systech Get an inside look… Merck shares its next-generation approach to supply chain protection with new digital platforms, including Blockchain. Sponsored by: Automation Anywhere Built on advances in Artificial Intelligence (AI), data mining, and information integration into various systems at 100% accuracy, the new era of intelligent automation is integral to life sciences for devising new treatments faster and at a lower expense. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. The Bioprocessing Summit Virtual – Solving Today’s Challenges, Leading to Tomorrow’s Advances August 24-28, 2020 Drug Development Boot Camp® 2020 November 18-19, 2020 | Register now! Pre-Boot Camp training ongoing now. | COVID19 provisions – training will be on-site as normal. | New – may be possible for some individuals to access the training virtually in real time. | 